The role of piperacillin therapy in pulmonary exacerbations of cystic fibrosis: a controlled study.
Piperacillin was evaluated as an antipseudomonas antibiotic in a double-blind controlled trial involving 18 pulmonary exacerbations of cystic fibrosis. Standard antibiotic treatment (flucloxacillin plus tobramycin) was compared with standard treatment plus intravenous piperacillin administered according to two regimens. No added benefit from piperacillin was demonstrable on the basis of improvement in symptoms, physical signs, weight gain, pulmonary function tests, radiologic signs, or sputum Pseudomonas bacterial counts. Some patients experienced sensitivity reactions to piperacillin. In vitro, piperacillin was a potent antibiotic against all beta-lactamase-producing mucoid strains of Pseudomonas aeruginosa; however, in spite of the fact that adequate serum antibiotic concentrations were achieved, sputum bacterial counts did not correlate with either the clinical status or the use of piperacillin therapy.
D000293:Adolescent; D000617:Aminoglycosides / Q000627:therapeutic use; D002648:Child; D002986:Clinical Trials as Topic; D003550:Cystic Fibrosis / Q000150:complications*; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005436:Floxacillin / Q000627:therapeutic use; D006801:Humans; D008171:Lung Diseases / Q000188:drug therapy* / Q000209:etiology; D010878:Piperacillin / Q000008:administration & dosage / Q000627:therapeutic use*; D011339:Probenecid / Q000627:therapeutic use; D011552:Pseudomonas Infections / Q000188:drug therapy* / Q000209:etiology; D012129:Respiratory Function Tests; D014031:Tobramycin / Q000627:therapeutic use
D000617:Aminoglycosides; D005436:Floxacillin; D011339:Probenecid; D014031:Tobramycin; D010878:Piperacillin